Priscilla K Brastianos

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
    Priscilla K Brastianos
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Broad Institute, Boston, Massachusetts
    Cancer Discov 5:1164-77. 2015
  2. doi request reprint Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
  3. doi request reprint Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
  4. doi request reprint The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Smith 353, Boston, MA 02115, USA
    J Neurooncol 106:81-8. 2012
  5. pmc Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
    Lori A Ramkissoon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:8188-93. 2013
  6. pmc Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 45:285-9. 2013
  7. doi request reprint Rapid Intraoperative Molecular Characterization of Glioma
    Ganesh M Shankar
    Department of Neurosurgery, Massachusetts General Hospital, Boston2Cancer Program, Broad Institute, Cambridge, Massachusetts
    JAMA Oncol 1:662-7. 2015
  8. pmc Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla K Brastianos
    1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 2 Division of Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 3 Harvard Medical School, Boston, Massachusetts, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 5 Broad Institute of MIT and Harvard, Boston, Massachusetts, USA 6
    Nat Genet 46:161-5. 2014
  9. ncbi request reprint VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
  10. pmc Sporadic hemangioblastomas are characterized by cryptic VHL inactivation
    Ganesh M Shankar
    Departments of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA
    Acta Neuropathol Commun 2:167. 2014

Collaborators

Detail Information

Publications16

  1. doi request reprint Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
    Priscilla K Brastianos
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Broad Institute, Boston, Massachusetts
    Cancer Discov 5:1164-77. 2015
    ..Genomic analysis of brain metastases provides an opportunity to identify potentially clinically informative alterations not detected in clinically sampled primary tumors, regional lymph nodes, or extracranial metastases...
  2. doi request reprint Primary central nervous system lymphoma: overview of current treatment strategies
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Division of Hematology and Oncology, Department of Neurology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Hematol Oncol Clin North Am 26:897-916. 2012
    ..The standard treatment is a methotrexate-containing chemotherapy regimen. The timing and dose of whole-brain radiation therapy is controversial, given the significant risks of late neurotoxic effects, particularly in elderly patients...
  3. doi request reprint Vascular endothelial growth factor inhibitors in malignant gliomas
    Priscilla K Brastianos
    Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
    Target Oncol 5:167-74. 2010
    ..Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy...
  4. doi request reprint The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Smith 353, Boston, MA 02115, USA
    J Neurooncol 106:81-8. 2012
    ..The median survival of evaluable rabbits with LC treated with intraventricular saline (N = 13) was 15 days compared to 18 days for the animals receiving VX2 and one dose of BCM (N = 12)...
  5. pmc Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1
    Lori A Ramkissoon
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 110:8188-93. 2013
    ..Our results define clinically relevant molecular subclasses of diffuse PLGGs and highlight a potential role for the MYB family in the biology of low-grade gliomas...
  6. pmc Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Nat Genet 45:285-9. 2013
    ..These mutations were present in therapeutically challenging tumors of the skull base and higher grade. These results begin to define the spectrum of genetic alterations in meningiomas and identify potential therapeutic targets...
  7. doi request reprint Rapid Intraoperative Molecular Characterization of Glioma
    Ganesh M Shankar
    Department of Neurosurgery, Massachusetts General Hospital, Boston2Cancer Program, Broad Institute, Cambridge, Massachusetts
    JAMA Oncol 1:662-7. 2015
    ..Therefore, we developed a rapid and sensitive genotyping assay to detect somatic single-nucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1)...
  8. pmc Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas
    Priscilla K Brastianos
    1 Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 2 Division of Neuro Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA 3 Harvard Medical School, Boston, Massachusetts, USA 4 Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA 5 Broad Institute of MIT and Harvard, Boston, Massachusetts, USA 6
    Nat Genet 46:161-5. 2014
    ..Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms. ..
  9. ncbi request reprint VEGF inhibitors in brain tumors
    Priscilla K Brastianos
    Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
    Clin Adv Hematol Oncol 7:753-60, 768. 2009
    ..Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis...
  10. pmc Sporadic hemangioblastomas are characterized by cryptic VHL inactivation
    Ganesh M Shankar
    Departments of Neurosurgery, Massachusetts General Hospital, Boston, MA, USA
    Acta Neuropathol Commun 2:167. 2014
    ..Our findings support the central role of VHL inactivation in the molecular pathogenesis of both familial and sporadic hemangioblastomas...
  11. doi request reprint Genomic profiling of brain metastases: current knowledge and new frontiers
    Martha R Neagu
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Chin Clin Oncol 4:22. 2015
    ..This review focuses on advances made in the understanding of the genomics of BM and how this may change the role of targeted therapeutics in this common complication of cancer. ..
  12. pmc Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5
    Malak S Abedalthagafi
    Department of Pathology, Division of Neuropathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Oncotarget 5:10596-606. 2014
    ..Our study demonstrates that angiomatous meningiomas have distinct genomic features that may be clinically useful for their diagnosis...
  13. ncbi request reprint Clinical discussion and review of the management of brain metastases
    Priscilla K Brastianos
    From the aDepartment of Medicine, Division of Hematology Oncology, bDepartment of Neurosurgery, and cDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts
    J Natl Compr Canc Netw 11:1153-64. 2013
    ..This article outlines the various therapeutic modalities, factors that guide treatment decisions, and medical management of frequently encountered complications of brain metastases. ..
  14. doi request reprint Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
    Justin F Gainor
    Department of Medicine, Massachusetts General Hospital, Boston, MA Electronic address
    J Thorac Oncol 11:256-60. 2016
    ....
  15. doi request reprint PLEKHA5: A Key to Unlock the Blood-Brain Barrier?
    Sylvia C Eisele
    Division of Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    Clin Cancer Res 21:1978-80. 2015
    ..PLEKHA5 functions as a regulator of brain metastasis in melanoma, and further investigation is warranted to explore the use of PLEKHA5 as a potential therapeutic target...
  16. pmc Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
    Ziming Du
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Oncotarget 6:4704-16. 2015
    ..This work indicates that high-grade meningioma harbor an immunosuppressive tumor microenviroment and that increased Treg cells and elevated PD-L1 may contribute to the aggressive phenotype of these tumors. ..